NEPTUNUS(SZ:000078)2022-12-08 03:12Group 1: Company Overview - Shenzhen Haiwang Biological Engineering Co., Ltd. is engaged in pharmaceutical commerce, pharmaceutical industry, and innovative development [1][2]. - The company has been transitioning from traditional pharmaceuticals to new types of pharmaceuticals, with a current net profit margin of 1.6% [3]. Group 2: Business Strategy - Haiwang Biological has been focusing on centralized procurement and sunshine distribution since 2003, with significant growth in profit margins expected as the company learns from its subsidiaries [3][4]. - The company is exploring horizontal expansion in specific regions and vertical integration with hospitals, which includes centralized distribution and professional pharmacy services [4][5]. Group 3: Market Position and Competition - The company aims to maintain a competitive edge in the market, with a sales target of 20 billion expected to saturate the terminal market [4][5]. - Haiwang Biological has a strong confidence in its products due to patent support and a high success rate in bidding processes [5][6]. Group 4: Future Plans - There are plans for potential acquisitions of hospitals and other medical resources, as demonstrated by a recent investment in a hospital project [5][6]. - The company is also looking to expand its online presence through O2O (Online to Offline) strategies, leveraging its extensive product range [6][7].